HALOZYME THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $14.85B
- P/E (TTM)
- 36.1
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $481.00M | $1.90 | $2.28 |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | After market close | $376.70M | $1.22 | $1.60 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 17, 2026 | After market close | $451.80M | $-1.20 | $-0.24 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | After market close | $354.30M | $1.43 | $1.72 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | After market close | $325.70M | $1.33 | $1.54 |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | $264.90M | $0.93 | $1.11 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 18, 2025 | After market close | $298.00M | $1.06 | $1.26 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 31, 2024 | After market close | $290.10M | $1.05 | $1.27 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | $231.40M | $0.72 | $0.91 |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 20, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDA growthnon-GAAP | full year 2026 | 86% to 95% growth | Raised |
| Adjusted EBITDAnon-GAAP | full year 2026 | $1.23B to $1.28B | Raised |
| Non-GAAP diluted earnings per share growthnon-GAAP | full year 2026 | 108% to 117% growth | Raised |
| Non-GAAP diluted earnings per sharenon-GAAP | full year 2026 | $8.65 to $9.00 | Raised |
| Revenue from royalties growth | full year 2026 | 41% to 43% growth | Raised |
| Revenue from royalties | full year 2026 | $1.22B to $1.25B | Raised |
| Total revenue growth | full year 2026 | 31% to 37% growth | Raised |
| Total revenue | full year 2026 | $1.84B to $1.91B | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Halozyme Therapeutics filed with the SEC
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
Other events · EX-99.1 to Form 8-K
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
Other events · EX-99.1 to Form 8-K
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Results of operations · EX-99.1 to Form 8-K
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
Results of operations · EX-99.1 to Form 8-K
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
Results of operations · EX-99.1 to Form 8-K
Halozyme Raises 2025 Revenue Estimates,
Results of operations · EX-99.1 to Form 8-K
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of
Other events · EX-99.1 to Form 8-K
Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
Results of operations · Executive or director change · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative
Regulation FD disclosure · EX-99.1 to Form 8-K
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS
Results of operations · EX-99.1 to Form 8-K
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
Results of operations · EX-99.1 to Form 8-K
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE of $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA and NON-GAAP DILUTED EPS
Results of operations · EX-99.1 to Form 8-K
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
Results of operations · EX-99.1 to Form 8-K
HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS
Results of operations · EX-99.1 to Form 8-K
HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
Results of operations · EX-99.1 to Form 8-K
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
Results of operations · EX-99.1 to Form 8-K
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
Results of operations · EX-99.1 to Form 8-K
HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
Results of operations · EX-99.1 to Form 8-K
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
Results of operations · EX-99.1 to Form 8-K
HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS
Results of operations · EX-99.1 to Form 8-K
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
Regulation FD disclosure · EX-99.1 to Form 8-K
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS
Results of operations · EX-99.1 to Form 8-K
Halozyme Provides 2023 Financial Guidance and Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Halozyme Confidential and Proprietary 1 41st Annual J.P. Morgan Healthcare Conference Dr. Helen Torley, President and CEO January 10, 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS
Results of operations · EX-99.1 to Form 8-K
Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of
Other events · EX-99.1 to Form 8-K
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million
Other events · EX-99.1 to Form 8-K
HALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS
Results of operations · EX-99.1 to Form 8-K
Halozyme Completes Antares Pharma Acquisition
Material agreement · Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
HALOZYME REPORTS FIRST QUARTER 2022 RESULTS
Results of operations · EX-99.1 to Form 8-K
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Halozyme to Acquire Antares Pharma
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS
Results of operations · EX-99.1 to Form 8-K
HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Halozyme Confidential and Proprietary 40th Annual J.P. Morgan Healthcare Conference Dr. Helen Torley, President and CEO January 10, 2022
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
HALOZYME REPORTS THIRD QUARTER 2021 RESULTS
Results of operations · EX-99.1 to Form 8-K/A